HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 1, 2010, Pages 51-61

  Geller, David S ^a   Gorlick, Richard ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b YESHIVA UNIVERSITY   (United States)

Author keywords

HER 2; HER 2 ErbB2; Herceptin ; Osteogenic sarcoma; Osteosarcoma; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; TRASTUZUMAB; TUMOR MARKER;

BRAIN TUMOR; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENICITY; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE FREE INTERVAL; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; EWING SARCOMA; HUMAN; LUNG CANCER; LUNG METASTASIS; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS; ONCOGENE NEU; OSTEOSARCOMA; OVARY CANCER; PRIMARY TUMOR; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; RHABDOMYOSARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; KALLIKREINS; OSTEOSARCOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 72849133542     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903419614     Document Type: Review

References (47)

1. McKenna RJ, Schwinn CP, Soong KY. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone). An analysis of 552 cases. J Bone Joint Surg Am 1966;48-A:1-26
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009;115:1531-1543
3. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229-234
4. Cancer Facts and Figures 2008. Atlanta: American Cancer Society, Inc., 2008
5. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LA, Smith MAS, Gurney JG, et al, editors, Cancer incidence and survival among children and adolescents: United States SEER program 1975 - 1995 (Pub #99-4649), SEER program. Bethesda, MD: National Cancer Institute; 1999. p. 99-110
6. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989
7. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606
8. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-26
9. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;270:8-14
10. Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006;7:444-455
11. Patel SJ, Lynch JW Jr, Johnson T, et al. Dose-intense ifosfamide/doxorubicin/ cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 2002;25:489-495
12. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-2039
13. Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma - a Phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-825
14. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638
15. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115(22):5339-5348
16. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 2007;96:118-123
17. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970 - 2000). Cancer 2004;100:1928-1935
18. Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005;41:578-583
19. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790
20. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988;85:5394-5398
21. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245
22. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996;3:99-105
23. Bongiorno PF, Whyte RI, Lesser EJ, et al. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 1994;107:590-595
24. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78
25. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788
26. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32
27. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84:113-121
28. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404
29. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-1942
30. Bakhshi S, Gupta A, Sharma MC, et al. Her-2/neu, p-53, and their coexpression in osteosarcoma. J Pediatr Hematol Oncol 2009;31:245-251
31. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41:1349-1361
32. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-683
33. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/ neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-1283
34. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-793
35. Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-2053
36. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963-970
37. Somers GR, Ho M, Zielenska M, et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 2005;8:525-532
38. Willmore-Payne C, Holden JA, Zhou H, et al. Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 2006;130:691-698
39. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777
40. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-682
41. Roychowdhury DF, Tseng A Jr, Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 1996;77:1419-1426
42. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-608
43. Kay EW, Mulcahy H, Walsh CB, et al. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-461
44. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-1654
45. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721
46. Hughes DP, Thomas DG, Giordano TJ, et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 2006;46:614-623
47. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009;53:594-598